Knowing stock market today at a glance

Gilead Sciences (GILD) Plunges 3.52% on Earnings Miss, Restructuring

Mover TrackerFriday, Apr 25, 2025 4:08 am ET

1min read

Gilead Sciences' stock price dropped by 3.52% in pre-market trading on April 25, 2025, reflecting investor concerns and market reactions to recent developments.

Gilead Sciences has been actively restructuring its operations, including significant layoffs and the closure of certain facilities. The company has announced plans to end operations at its Kite Pharma factory in Philadelphia by mid-2025, and there have been reports of layoffs in its China division. These moves are part of Gilead's strategy to optimize resources and focus on key products, such as the HIV prevention drug lenacapavir, which is expected to be administered twice a year.

Gilead's first-quarter earnings report showed mixed results. While the company exceeded earnings expectations with $1.81 per share, it fell short of revenue estimates, reporting $6.67 billion compared to the anticipated $6.77 billion. This revenue shortfall was primarily due to a decrease in Veklury sales, which dropped by 45% to $302 million, reflecting lower COVID-19 hospitalizations. Despite this, HIV product sales increased by 6% to $4.6 billion, driven by higher prices and demand for Biktarvy.

Gilead's CEO, Daniel O'Day, highlighted the company's strong commercial and clinical execution, as well as disciplined expense management. However, the company lowered its fiscal 2025 earnings guidance to a range of $5.65 to $6.05 per share, down from the previous range of $5.95 to $6.35 per share. This adjustment reflects the challenges Gilead faces in maintaining revenue growth amidst a changing market landscape.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.